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The individual response to drug therapy may vary greatly, making the success of a given 
treatment strategy difficult to predict, particularly because multiple factors influence drug 
response. In addition to age sex, comorbidity, renal and hepatic function, the role of genetic 
factors that determine an individual’s response to drug treatment is increasingly being realized. 
Genetic differences influencing the pharmacokinetics of a drug may exist at the level of drug 
metabolism determined by several well characterised phase I and phase II enzymes, with 
cytochrome P450 being the most important metabolizing system. Drug disposition is not only 
influenced by metabolizing enzymes but also by transport proteins, that play an important role in 
the processes of drug absorption, distribution and excretion. In addition to pharmacokinetic 
determinants pharmacodynamic effects of a drug may be determined by genetic differences in the 
drug target. Although to date an increasing number of genetic polymorphisms (SNPs) in single 
genes has been associated with variability of protein function and drug disposition, dose-response 
is generally influenced by a whole spectrum of genes, making analysis of a single gene 
insufficient to explain the variability of a pharmacological effect. Despite this complex 
interaction of factors determining drug response, several examples of direct genotype-phenotype 
relations have been discovered, that have led to the development of routine diagnostic tools for 
the individualization of drug dosing regimens. 
Drug metabolizing enzymes 
Drug metabolizing enzymes are subdivided into two categories: phase-I and phase-II enzymes. 
Phase I enzymes are responsible for the oxidative degradation (oxidation, reduction, hydrolysis) 
of endogenous substances (e.g. steroids) and xenobiotics. Phase-II enzymes render the 
coumpounds more water-soluble mainly by glucuronidation, sulfation, acetylation and 
methylation. The most important phase I enzyme system is cytochrome P450 (CYP), that 
metabolizes the majority of pharmacological compounds (50-60%). As many as 57 CYP genes 
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have been characterized, among these only the enzymes encoded by CYP1, CYP2 and CYP3 
genes seem to contribute to the metabolism of drugs [1]. Almost all of the CYP isoforms possess 
genetic polymorphisms, the CYP2 family exhibiting the highest genetic variability with a distinct 
clinical impact. CYP2D6 is the best characterized isoenzyme and is responsible for the 
metabolism of most antipsychotics and antidepressants and several antiarrhythmics. In 6-10% of 
Caucasians and 1% of Asians the enzymatic activity is completely absent resulting in a “poor 
metabolizer” (PM) phenotype and leading to increased exposure and toxicity of drugs 
metabolized by CYP2D6 [2]. Some individuals possess multiple copies of the gene expressing 
the ultra-rapid metabolizer (UM) phenotype resulting in subtherapeutic plasma concentrations at 
normal doses [3]. About 3% of Caucasians carry the CYP2C9 or CYP2C19 PM phenotype 
predisposing them to an increased anticoagulatory effect of s-warfarin and increased toxicity of 
the antiepileptic drug phenytoin. For many drugs conjugation by phase-II enzymes represents the 
main metabolic pathway, although these are not as well characterized as the oxidative enzymes. 
Nevertheless a few important polymorphisms have been identified. Thiopurine S-
methyltransferase (TPMT) catalyzes the S-methylation of azathioprine (AZA), 6-mercapto-
purine (6-MP) and thioguanine. TPMT activity exhibits genetic polymorphisms in 10% of 
Caucasians, with 1/300 individuals having a complete deficiency that leads to an increased risk 
for fatal myelosuppression [4]. Toxicity of the antituberculostatic agent isoniazid has been 
associated with a reduced activity of the enzyme N-acetyltransferase-2. Life-threatening diarrhea 
and leukopenia is observed in up to 25% of patients receiving the anti cancer drug irinotecan and 
has been related to polymorphisms in the uridine diphosphate-glucuronosyltransferase (UGT)-
1A1 gene [5]. For most of the described enzymes routine genotyping is established which makes 
an individual dose adaptation possible.  
Drug transporters 
An increasing list of transport proteins have been found to play an important role in regulating 
drug uptake from intestine and sinusoidal blood into the liver, in regulating and limiting drug 
distribution to different body compartments like central nervous system and in controlling drug 
efflux into bile and renal tubule [6]. Thus genetic polymorphisms in human membrane 
transporters may also contribute to interindividual differences in drug response. The transport 
proteins described to date that are involved in transmembrane drug transport include the ATP-
binding cassette (ABC) transporters MDR1 (multidrug resistance protein 1), BSEP (bile salt 
export pump), MRP1, 2, 3 and 4 (multidrug resistance associated protein 1, 2, 3 and 4) and 
BCRP/ABCG2 (breast cancer resistance protein) found in the basolateral or canalicular 
membrane of liver cells and some of them in the kidney. Organic anion and cation transporters 
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like the organic anion transporting polypeptides (OATP) are mainly responsible for drug uptake 
into the hepatocyte and the organic anion and cation tranporters (OAT/OCT) for the renal tubular 
secretion and reabsorption of drugs. Multiple SNPs and haplotypes have been characterized in 
the MDR1 gene (ABCB1) and its gene product p-glycoprotein (p-gp), which has been recognized 
to play a primary role in drug disposition [7]. Although data on the functional effect of the 
variant MDR1-alleles are not always conclusive and sometimes contradictory, the SNP 3435TT 
in exon 26 was associated with reduced intestinal expression of p-gp. Oral bioavailability of 
digoxin, the most extensively studied p-gp substrate, was significantly higher in individuals 
carrying the genotype 3435CC [8]. Enhanced p-gp activity was found in subjects with the 
3435TT/G2677T genotype, causing a 40% reduction in AUC values following oral 
administration of the p-gp substrate fexofenadine, when compared to the 3435CC genotype [9]. 
MRP2 plays a central role in the biliary excretion of organic anions such as many anticancer 
drugs. Recently a mutation in exon 10 of the MRP2 gene was shown to confer loss of transport 
activity, leading to methotrexate overdose with renal failure [10]. The organic anion transporting 
polypeptide 1B1 (OATP1B1) and multidrug resistance-associated protein 2 (MRP2 / ABCC2), 
are thought to be the major transporters determining in the pharmacokinetics of pravastatin in 
humans. A genetic polymorphism in the OATP1B1 (SLCO1B1) gene led to a reduced total and 
renal clearance of pravastatin in healthy Japanese individuals [11]. 
It is now evident that hepatocellular transport proteins are also important in determining the 
exposure of the liver to drugs and they may therefore be involved in the onset of drug induced 
liver injury[12, 13]. Reduced canalicular efflux transport protein activity can lead to intracellular 
bile acid and drug accumulation resulting in liver cell damage. A polymorphism in 
BSEP/ABCB11 with a valine-to-alanine exchange in the highly conserved amino acid position 
444 of the BSEP protein has been associated with a decreased hepatic content of BSEP [14]and 
with a threefold increased risk to develop cholestatic drug side effects [15].  
Drug targets 
Genetic polymorphisms in drug targets can have a major influence on the effect of a drug. To 
date more than 20 examples of drug targets with genetic variability that directly influences drug 
response have been identified. The anticoagulatory effect of warfarin is determined on the one 
hand by the genotype and activity of the metabolizing enzyme CYP2C9 and on the other hand by 
the genetic variability of the target enzyme Vitamin K epoxide reductase (VKOR) [16]. 
Homozygous mutations in the β1-adrenergic receptor reduces sensitivity to beta blocking agents 
in the treatment of arterial hypertension [17] and a correlation has also been seen between 
mutations in the β2-adrenergic receptor and response to oral β2-agonists [18]. Interindividual 
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response and increased toxicity of psychotropic substances such as antidepressants and 
antipsychotics can be defined by the genotype of the corresponding receptor type [19, 20]. 
Recently several examples of genetic variability in proteins targeted by monoclonal antibodies 
have been found to cause an insufficient drug effect. A study with 200 patients suffering from 
Crohn’s Disease showed a significant association between the biological response to infliximab, 
a chimeric antibody binding tumor-necrosis-factor-α, and a single nucleotide polymorphism in 
the FCGR3A gene, which codes for a receptor for the Fc fragment of IgG (FccR) on natural 
killer cells and macrophages [21]. In breast cancer therapy, copy number or expression levels of 
the HER2 gene that encodes a transmembrane tyrosine kinase receptor expressed on breast 
cancer cells, is highly associated with the therapeutic efficacy of the monoclonal antibody 
trastuzumab which inhibits the proliferation of tumor cells overexpressing HER2 [22] 
Conclusion 
The discovery of further genotype-phenotype associations will define the role of 
pharmacogenetics in future clinical practice. Genotype-based prescribing could improve response 
rate and decrease the socio-economic burden of adverse events. Nevertheless the effects of most 
drugs are determined by several proteins, and composite genetic polymorphisms in multiple 
genes coupled with non genetic factors often have a high impact on individual drug response. 
New strategies are therefore needed to identify, for a given drug, the relevant genes: these 
include (i) genome-wide haplotype mapping, (ii) gene expression analyses, (iii) proteomic 
methods, and (iv) candidate gene approaches based on known pharmacokinetic and 
pharmacodynamic factors. These approaches, coupled with evolving biostatistical models, will 
elucidate polygenic determinants of drug response. Clinical validation of these polygenic models 
requires large clinical trials of uniformly treated and systematically characterized patients, high-
throughput genomic methods, and sophisticated bioinformatic analyses. These studies could 
yield an exciting new panel of molecular diagnostics (i.e. genotypes) that can be employed to 
improve drug therapy by reducing toxicity and increasing efficacy. 
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